CD274 and neoplasm: Current treatment options for all NSCLCs include chemotherapy, radiotherapy, molecular targeted therapy, and immunotherapy, with subsets of patients treated according to the genetic alterations of their tumor and the status of programmed death ligand-1 (PD-L1), which predict for benefit from targeted therapies or immune checkpoint blockers, respectively [3,4].